The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A pilot study of neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab in patients with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC).
 
Lara Dunn
Consulting or Advisory Role - Merck
Research Funding - CUE Biopharma; Nektar; Regeneron; Replimune
 
Eric Jeffrey Sherman
Consulting or Advisory Role - Blueprint Medicines; Eisai; Exelixis; Lilly; UpToDate
Research Funding - HUTCHMED (Inst); Lilly (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron (Inst)
 
Alan Loh Ho
Consulting or Advisory Role - AffyImmune Therapeutics; AstraZeneca; Ayala Pharmaceuticals; Bristol-Myers Squibb; Cellestia Biotech; CureVac; CureVac; Eisai; Eisai; Exelixis; Genzyme; InxMed; Kura Oncology; McGivney Global Advisors; Merck; Novartis; Prelude Therapeutics; Regeneron; Rgenta; Sanofi; Sun Pharma; TRM Oncology
Speakers' Bureau - Medscape; Novartis; Omniprex America
Research Funding - Allos Therapeutics; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Ayala Pharmaceuticals; Ayala Pharmaceuticals; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Elevar Therapeutics; Genentech/Roche; Kolltan Pharmaceuticals; Kura Oncology; Lilly; Merck; Novartis; Novartis; Novartis; Novartis; Pfizer
Travel, Accommodations, Expenses - Ayala Pharmaceuticals; Ignyta; Janssen Oncology; Klus Pharma; Kura Oncology; Kura Oncology; Kura Oncology; Merck
 
Ian Ganly
No Relationships to Disclose
 
Nadeem Riaz
Honoraria - PeerView
Consulting or Advisory Role - Mirati Therapeutics; Repare Therapeutics
Speakers' Bureau - Illumina
Research Funding - Bristol-Myers Squibb; Paige.AI; Pfizer; Repare Therapeutics
Travel, Accommodations, Expenses - Varian Medical Systems
 
Luc Morris
Research Funding - AstraZeneca
Patents, Royalties, Other Intellectual Property - employer pending patent application, listed as inventor (Inst)
 
Kin Wai (Tony) Hung
No Relationships to Disclose
 
Anuja Kriplani
No Relationships to Disclose
 
Jennifer R. Cracchiolo
No Relationships to Disclose
 
Marc Cohen
No Relationships to Disclose
 
Jay Boyle
No Relationships to Disclose
 
Snehal G. Patel
Patents, Royalties, Other Intellectual Property - PCT/US2014/073053; PCT/US2015/065816; PCT/US2016/026717; PCT/US2016/066969
 
Sofia Haque
Honoraria - Advance Medical
Consulting or Advisory Role - Advance Medical
 
Nora Katabi
No Relationships to Disclose
 
Ronald A Ghossein
No Relationships to Disclose
 
Sean Matthew McBride
Consulting or Advisory Role - AstraZeneca; Janssen
Research Funding - AstraZeneca; Genentech
 
Loren S. Michel
Research Funding - Exelixis (Inst)
(OPTIONAL) Uncompensated Relationships - Abbvie
 
Richard J. Wong
No Relationships to Disclose
 
Nancy Y. Lee
Consulting or Advisory Role - Merck; Merck Serono; Mirati Therapeutics; pfizer; Roche/Genentech; Sanofi
Research Funding - AstraZeneca; Pfizer (Inst)
 
David G. Pfister
Consulting or Advisory Role - Boehringer Ingelheim; Incyte
Research Funding - AstraZeneca (Inst); Atara Biotherapeutics (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Hookipa Pharma (Inst); Lilly (Inst); MedImmune (Inst); MeiraGTx (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst)